Insider Selling: Evan/ Fa Jones Sells 28,248 Shares of Veracyte Stock (VCYT)
Veracyte (NASDAQ:VCYT) Director Evan/ Fa Jones sold 28,248 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $14.33, for a total value of $404,793.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Veracyte (NASDAQ:VCYT) traded up 0.42% on Thursday, hitting $14.38. The stock had a trading volume of 57,791 shares. Veracyte has a 52-week low of $10.88 and a 52-week high of $19.00. The stock’s 50-day moving average is $13.61 and its 200-day moving average is $14.70. The company’s market cap is $304.5 million.
Veracyte (NASDAQ:VCYT) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter in the previous year, the company posted ($9.04) earnings per share. The company’s revenue for the quarter was up 70.5% on a year-over-year basis. Analysts expect that Veracyte will post $-1.32 EPS for the current fiscal year.
A number of analysts have recently weighed in on VCYT shares. Analysts at Cowen and Company raised their price target on shares of Veracyte from $17.00 to $22.00 in a research note on Wednesday, March 19th. They now have an “outperform” rating on the stock. Analysts at Leerink Swann raised their price target on shares of Veracyte from $21.00 to $23.00 in a research note on Wednesday, March 19th.
Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.